Toronto Health Innovation Week – 2018

By Gregory Mannix, Vice President International Business Development, LSN

Where Health Means Business
For the second year running, RESI on MaRS will be the centerpiece event of the Toronto Health Innovation Week, taking place from April 9th to 13th, 2018. 30+ events will be taking place that week in the Toronto Region, bringing together key players in the life sciences from Canada and around the globe. Life science entrepreneurs, investors, opinion leaders and many others will converge on the region for an intense week of partnering and discussions. Here are some of the highlights:

Impact Health Summit. April 9th (All day)
Industry leaders and stakeholders from Canada and the world come together to build new partnerships and accelerate the ecosystem. The day will include keynotes and panels from industry leaders, roundtables, workshops and the Health Partnering Forum.

HealthKick Investor Summit. April 9th (Afternoon)
An inside look at the emerging trends, opportunities and challenges shaping the investment climate for human health and life sciences. Gain insight into the state of financing in healthcare today and the industry developments driving investments.

RESI on MaRS. April 10th (All day)
350+ global investors and strategics will meet 350+ early-stage life science companies and quality service providers in the industry’s premier partnering event for funding.

Also Offering Premier Partnering Plus

For more information: https://www.healthinnovationweek.ca/

Are You Ready For RESI JPM? Time To Check Out The Program Guide

By Nono Hu, Director of Marketing, LSN

JPM week is almost upon us, and at Life Science Nation, we’re making the final preparations for RESI San Francisco. It’s our largest event of the year; if you want to join over a thousand life science executives and investors for targeted one-on-one meetings, you’ve got 5 more days to sign up. In the meantime, please check out the RESI Program Guide below to see all our RESI Innovators, sponsors, exhibitors and speakers. With attendees from all over the world coming to RESI to make new connections and continue compelling dialogues, RESI San Francisco is the most focused event next week for early stage companies and investors. We’ll look forward to seeing you all face to face next week.

Over 400 Qualified Life Science Investors Registered For Redefining Early Stage Investments (RESI) Conference at JP Morgan, Jan 9th at Marine Memorial Hotel, Union Square

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI is different, in that, the LSN research team actually qualifies all the investors that attend the RESI conference. The LSN researchers, through one-on-one phone conversations, validate that all the investors have current or future mandates to invest in early stage technology assets across the domains of drugs, devices, diagnostics or healthcare IT. Fundraising CEOs and scientist entrepreneur’s don’t have to guess who they are meeting with on the other side of the table. As a matter of fact, we kindly ask the I-banks, broker dealers and debt providers to sign up as service providers so the fundraisers know who’s who in the whirlwind of meetings taking place at RESI. This will be our fourth RESI @ JPM and we expect to close down registrations due to the capacity constraint on the Marine Memorial Hotel in Union Sq. The good news is we are still accepting registrations “click here to register”.

RESI @ JPM will be the most compelling event LSN has held because the investor to fundraiser ratio will be 1-to-1, as amazing as that sounds. If you are a fundraising executive please take advantage of this opportunity to meet investors that are a fit for your stage of development and product set. RESI Partnering is now up and running with half of the meetings now booked. There is still time to dramatically impact the number of investors on your radar screen. Raising money is a numbers game, and RESI was created to help identify investors that are a fit, create a dialogue, and foster relationships that help you move towards allocations. Please scroll down and see the investors currently signed up for RESI at JPM.

Big Pharma Firms Head Upstream For New Pipeline Assets – Learn Their Strategies at RESI

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking to startups to supply new assets for their pipelines, and LSN’s research has found that many are interested in inking deals at the earliest stages of drug development. Going into 2017, we found that a plurality of pharma deals announced in the previous year concerned preclinical assets.

Due to RESI’s focus on early stage life science companies, the vent has become known as a venue for top pharma firms to uncover new therapeutic opportunities. At RESI San Francisco, the panel on Big Pharma will provide an opportunity to hear straight from five experienced scouts on what they’re looking for, how they make deals and what makes a pharma partnership work.

Moderated by Chris Haskell, VP, Head of West Coast Innovation Center, Bayer Healthcare, the panelists are:

  • Kevin Lynch, Vice President, Search & Evaluation, AbbVie
  • Chris Sheldon, Head, Oncology Search & Evaluation, AstraZeneca
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Chris DeRespino, Director Transactions, Amgen

Orphan Drug Investors Discuss the Current Rare Disease Environment during RESI@JPM

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

A large number of early stage biotechs are pursuing orphan disease indications.  This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:

Partnering: Transitioning Conferences from Information-Centric to Relationship-Centric

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation’s Redefining Early Stage Investments (RESI) conference is a partnering event that requires high touch on both the buy side (investors and pharma) and sell side (startup) constituents. To do partnering correctly takes a high human resource allocation; it is expensive to fund, and requires deep curation of a clientele database for each conference iteration. LSN has discovered that our database curation begets savvy list management, which in turn allows us to target constituents and provide them with customer support and training to use the partnering system efficiently. In today’s life science domain, conferences still lead as a place to make new business connections in addition to accessing the latest information on the advances in drugs, devices, diagnostics, and healthcare IT.

Informational-based life science conferences have worked for decades to successfully “break the profitability code”. Breaking the code means finding the precise point between internal resource output and maximum revenue gain, and balancing on it. The irony here is that if the conferences wish to be part of the industry’s new trend of relationship-based conferences with a strong partnering component, they will have to modify their view on resource allocation for partnering at their events. This may seem like a small issue that simply requires dedicating more resources to partnering, which causes a hit to the bottom line. However, it is actually a huge core issue that exposes an inherent dichotomy that must be traversed, or we will see a upheaval in the traditional conference market.

A lot of the information-based, super technical, scientific conferences that cater to academia and very early stage discoveries have found themselves in the crosshairs of big pharma and other large partners who are moving upstream to find technology that isn’t already identified and partnered up. This is another reason why these early stage scientific conferences are now in need of a partnering component, which will require higher capital spend and higher human resources to implement. This epiphany will go against the basic grain of the business philosophy of most of the conference providers. I will posit that if they don’t get partnering right, they will become vulnerable as there is a distinct and growing need from both buyers and sellers to build business connections at these conferences. The question is, can the conference providers change the lens on how they value their conferences?

The conference folks I talk to seem unconvinced that you really need a partnering effort that goes beyond a basic software application and a dedicated space at their venues. Indeed, it seems as if they are still trying to talk themselves into supporting partnering at all! Is this a fatal flaw?

Based on the 5 years of experience that I have garnered in the partnering conference marketplace, I will provide some of my insights. Great partnering is very hard to get right, it’s resource intensive and it is “high touch”. You do successful partnering by creating a consistent dialogue with your constituents. This entails focused marketing via newsletters promos, emails and phone canvassing. You need dedicated staff who reach out (yes, talk with!) and understand both the buy-side and sell-side needs of the clients. The staff’s job is to talk to the clients and understand their needs and keep a record of what the client needs, what technology they are interested in and who they are seeking to meet. If you initiate this compelling dialogue, it soon turns into a relationship, and having a direct relationship with your clients is the holy grail.

I also question whether the conference providers want great partnering or “me too” partnering? LSN’s style of interactive dialogue and relationship building through business development is very different than that of info-based conference organizations. LSN’s thesis is that we are NOT a conference company; we are a buyer seller matching platform with a conference, and that’s what gives RESI’s partnering platform its incredible power to forge new connections.

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital